Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to acquiring, developing, and commercializing novel therapeutics for cancer treatment. The company's flagship product, NERLYNX (neratinib), is an oral tyrosine kinase inhibitor approved in the United States and over 60 other countries for the extended adjuvant treatment of early-stage HER2-overexpressed/amplified breast cancer, as well as for advanced or metastatic HER2-positive breast cancer in combination with capecitabine. Beyond its commercialized product, Puma is actively advancing its clinical pipeline, notably through the ALISCA program. This program evaluates the in-licensed drug alisertib—a selective aurora kinase A inhibitor—for the treatment of extensive-stage small cell lung cancer and hormone receptor-positive metastatic breast cancer. The company generates its revenue primarily through the sale of NERLYNX to specialty pharmacies and distributors, supplemented by royalties from its international sub-licensees.
